Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Denali Therapeutics Inc. (DNLI) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $28.80 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $28.80.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $29.32.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $29.46.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $29.41.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $28.80 10-Q · filed 2026-08-06 |
| 2026-03-31 | $29.32 10-Q · filed 2026-05-07 |
| 2025-12-31 | $29.46 10-K · filed 2026-02-26 |
| 2025-09-30 | $29.41 10-Q · filed 2025-11-06 |
| 2025-06-30 | $28.16 10-Q · filed 2025-08-11 |
| 2025-03-31 | $28.35 10-Q · filed 2025-05-06 |
| 2024-12-31 | $28.61 10-K · filed 2025-02-27 |
| 2024-09-30 | $27.89 10-Q · filed 2024-11-06 |
| 2024-06-30 | $27.31 10-Q · filed 2024-08-01 |
| 2024-03-31 | $26.70 10-Q · filed 2024-05-07 |
| 2023-12-31 | $25.93 10-K · filed 2024-02-28 |
| 2023-09-30 | $25.28 10-Q · filed 2023-11-07 |
| 2023-06-30 | $24.47 10-Q · filed 2023-08-08 |
| 2023-03-31 | $23.63 10-Q · filed 2023-05-08 |
| 2022-12-31 | $21.71 10-K · filed 2023-02-27 |
| 2022-09-30 | $21.08 10-Q · filed 2022-11-03 |
| 2022-06-30 | $20.27 10-Q · filed 2022-08-08 |
| 2022-03-31 | $19.19 10-Q · filed 2022-05-05 |
| 2021-12-31 | $15.78 10-K · filed 2022-02-28 |
| 2021-09-30 | $15.22 10-Q · filed 2021-11-04 |
| 2021-06-30 | $14.67 10-Q · filed 2021-08-04 |
| 2021-03-31 | $14.01 10-Q · filed 2021-05-05 |
| 2020-12-31 | $14.28 10-K · filed 2021-02-26 |
| 2020-09-30 | $13.80 10-Q · filed 2020-11-05 |
| 2020-06-30 | $13.52 10-Q · filed 2020-08-07 |
| 2020-03-31 | $12.63 10-Q · filed 2020-05-07 |
| 2019-12-31 | $11.19 10-K · filed 2020-02-27 |
| 2019-09-30 | $11.02 10-Q · filed 2019-11-06 |
| 2019-06-30 | $10.17 10-Q · filed 2019-08-06 |
| 2019-03-31 | $8.74 10-Q · filed 2019-05-08 |
| 2018-12-31 | $4.50 10-K · filed 2019-03-12 |
| 2018-09-30 | $3.78 10-Q · filed 2018-11-08 |
| 2018-06-30 | $3.58 10-Q · filed 2018-08-09 |
| 2018-03-31 | $3.32 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |